



19 October 2021

## **ASX ANNOUNCEMENT**

### **ImpediMed Investor Conference Call Notification**

ImpediMed Limited (ASX:IPD) advises it will hold an investor conference call to discuss the results of the PREVENT Trial.

Investors are invited to join a live webinar and Q&A hosted by Managing Director and CEO, Richard Carreon at 11.00am AEDT Tuesday 19 October 2021.

**To pre-register, please follow this link:**

<https://s1.c-conf.com/diamondpass/10017561-cm73hz.html>

*Registered participants will receive a calendar notification with dial in details and a PIN for fast-track access to the call.*

**Approved for release by the Managing Director and CEO, Mr Richard Carreon.**

#### **Contact Details**

**Investor relations Contact:**

Mike Bassett, ImpediMed

T: +61 407 431 432

E: [mbassett@impedimed.com](mailto:mbassett@impedimed.com)

#### **About ImpediMed**

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).